Performance of ASAP, LG2m, and GP73 for HCC Detection in Patients with Cirrhosis
Cancers · 21.08.2026 · 18 (16) · 2711
DOI: 10.3390/cancers18162711 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 21.08.2026. Verfasst von Mohammad Jarrah und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 75390, USA. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, Abbott Diagnostics.
Abstract (Originalsprache)
Background
The sensitivity of ultrasound plus alpha-fetoprotein (AFP) for early-stage hepatocellular carcinoma (HCC) detection remains suboptimal, prompting interest in blood-based biomarkers as an alternative strategy. The ASAP [age, sex, AFP, PIVKA-II] score has promising performance, although validation in contemporary Western populations is needed.
Methods
We conducted a case–control study in which the cases were patients with HCC and the controls had cirrhosis without HCC. AFP, PIVKA-II, LG2m, and GP73 were measured using the Abbott Alinity platform, and ASAP scores were calculated. Sensitivity and specificity for early-stage HCC (BCLC stage 0/A) were compared between ASAP and ultrasound plus AFP using McNemar’s chi-square test.
Results
Among 294 patients (median age of 61 years, 67.7% men), 50.7% had HCC (69.1% BCLC 0/A), and 49.3% had cirrhosis. The performance of individual biomarkers for early-stage HCC was moderate to poor (AUROC: AFP 0.71, PIVKA-II 0.73, LG2m 0.51, and GP73 0.53). ASAP, at a cutoff of ≥0.526, demonstrated a sensitivity of 88.3% for early-stage HCC, with specificity of 54.5%. Sensitivity was higher in men and viremic HCV, whereas specificity was higher in younger individuals, women, and Child–Pugh A cirrhosis. In subgroup analysis (n = 178), ASAP had comparable sensitivity to ultrasound plus AFP (85.5% vs. 90.3%; p = 0.51) but lower specificity (53.4% vs. 93.1%; p < 0.001). Using the Youden-optimized cutoff (≥0.804) improved specificity to 83.4% while maintaining a sensitivity of 68.0% for early-stage HCC.
Conclusions
ASAP demonstrated high sensitivity for early-stage HCC detection but low specificity. These findings suggest a need for optimized cutoffs prior to implementation in clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 75390, USA.
- Abbott Diagnostics, Abbott Park, IL 60064, USA.
ORCID-Profile: Mohammad Jarrah, Mohammed Al-Hasan, Maria V Yow, Jenna Bedrava, Claire Chen
Förderung
- NCI NIH HHS
- NIH HHS
- Abbott Diagnostics
- Cancer Prevention and Research Institute of Texas
- NIH
- CPRIT
- Abbott
Zitieren
APA
Jarrah, M., Al-Hasan, M., Yanez, M., Yow, M. V., Amador, E., Kar, D., Ahmed, F., Rich, N. E., Deodhar, S., Bedrava, J., Chen, C., & Singal, A. G. (2026). Performance of ASAP, LG2m, and GP73 for HCC Detection in Patients with Cirrhosis. Cancers, 18(16), 2711. https://doi.org/10.3390/cancers18162711
Vancouver
Jarrah M, Al-Hasan M, Yanez M, Yow MV, Amador E, Kar D, et al. Performance of ASAP, LG2m, and GP73 for HCC Detection in Patients with Cirrhosis. Cancers. 2026;18(16):2711. doi:10.3390/cancers18162711
BibTeX
@article{Jarrah2026,
author = {Jarrah, Mohammad and Al-Hasan, Mohammed and Yanez, Mariadelcarmen and Yow, Maria V and Amador, Eunice and Kar, Diya and Ahmed, Fouzia and Rich, Nicole E and Deodhar, Sneha and Bedrava, Jenna and Chen, Claire and Singal, Amit G},
title = {Performance of ASAP, LG2m, and GP73 for HCC Detection in Patients with Cirrhosis},
journal = {Cancers},
year = {2026},
volume = {18},
number = {16},
pages = {2711},
doi = {10.3390/cancers18162711}
}
EUVIMED